BRAF and metastatic malignant neoplasm in the lymph nodes: The rates of lymph node metastasis were 21.4% (18/84), 24.8% (38/153), 38.9% (7/18), and 43.8% (14/32) for PTMC harboring wild type (WT)-BRAF, PTMC harboring BRAF V600E mutation, PTC harboring WT-BRAF, and PTC harboring BRAF V600E mutation, respectively.